Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers-Sharing Experience.
glioblastoma
local drug delivery systems
partial resection model
rodent animal model
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
24 May 2023
24 May 2023
Historique:
received:
28
04
2023
revised:
19
05
2023
accepted:
22
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Local drug delivery systems (LDDS) represent a promising therapy strategy concerning the most common and malignant primary brain tumor glioblastoma (GBM). Nevertheless, to date, only a few systems have been clinically applied, and their success is very limited. Still, numerous new LDDS approaches are currently being developed. Here, (partial resection) GBM animal models play a key role, as such models are needed to evaluate the therapy prior to any human application. However, such models are complex to establish, and only a few reports detail the process. Here, we report our results of establishing a partial resection glioma model in rats suitable for evaluating LDDS. C6-bearing Wistar rats and U87MG-spheroids- and patient-derived glioma stem-like cells-bearing athymic rats underwent tumor resection followed by the implantation of an exemplary LDDS. Inoculation, tumor growth, residual tumor tissue, and GBM recurrence were reliably imaged using high-resolution Magnetic Resonance Imaging. The release from an exemplary LDDS was verified in vitro and in vivo using Fluorescence Molecular Tomography. The presented GBM partial resection model appears to be well suited to determine the efficiency of LDDS. By sharing our expertise, we intend to provide a powerful tool for the future testing of these very promising systems, paving their way into clinical application.
Identifiants
pubmed: 37371613
pii: biomedicines11061518
doi: 10.3390/biomedicines11061518
pmc: PMC10295193
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK2154
Organisme : European Regional Development Fund
ID : 122-09-053
Références
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Cancer Drug Resist. 2021;4:17-43
pubmed: 34337348
Cancers (Basel). 2020 Dec 26;13(1):
pubmed: 33375286
Nanomedicine (Lond). 2018 Aug;13(16):1999-2013
pubmed: 30204064
Oncotarget. 2017 Feb 14;8(7):12145-12157
pubmed: 28076333
J Neurosci Methods. 2014 Aug 15;233:99-104
pubmed: 24952322
Eur Radiol. 2016 Apr;26(4):1048-55
pubmed: 26188660
Ann Surg Oncol. 2008 Oct;15(10):2887-93
pubmed: 18636295
Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
pubmed: 16482400
J Neurosci Methods. 2017 Jun 1;284:96-102
pubmed: 28472680
J Neurooncol. 1989 Sep;7(3):299-304
pubmed: 2795124
Oncogene. 2008 May 1;27(20):2897-909
pubmed: 18037961
Clin Cancer Res. 2011 Jul 1;17(13):4296-308
pubmed: 21478334
BMC Cancer. 2018 Sep 3;18(1):871
pubmed: 30176837
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4
pubmed: 10841526
Front Oncol. 2021 Jan 29;10:614295
pubmed: 33585240
Surgery. 2011 Sep;150(3):497-504
pubmed: 21878236
Neurosurgery. 1997 Dec;41(6):1374-83; discussion 1383-4
pubmed: 9402589
Nat Commun. 2019 Nov 15;10(1):5205
pubmed: 31729383
Pharmaceutics. 2022 Apr 02;14(4):
pubmed: 35456611
AJNR Am J Neuroradiol. 2001 Jan;22(1):99-102
pubmed: 11158894
World Neurosurg. 2020 Sep;141:e633-e644
pubmed: 32522652
Neuro Oncol. 2015 Mar;17 Suppl 2:ii9-ii23
pubmed: 25746091
Sci Rep. 2022 Jul 8;12(1):11694
pubmed: 35803961
Neuro Oncol. 2013 Jan;15(1):41-56
pubmed: 23115160
ACS Biomater Sci Eng. 2020 Jun 8;6(6):3388-3397
pubmed: 33463157
Biol Pharm Bull. 2012;35(4):545-50
pubmed: 22466559
Br J Cancer. 1982 May;45(5):786-9
pubmed: 7082561
J Natl Cancer Inst. 1981 May;66(5):843-8
pubmed: 6939928
Clin Infect Dis. 2003 Mar 15;36(6):759-65
pubmed: 12627360
Cell Transplant. 2002;11(1):47-54
pubmed: 12095219
Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):397-407
pubmed: 24116348
Drug Resist Updat. 2015 Mar;19:1-12
pubmed: 25791797
Neuro Oncol. 2012 Aug;14(8):979-93
pubmed: 22679124
J Nucl Med. 2019 Oct;60(10):1373-1379
pubmed: 30850492
Nanomedicine (Lond). 2018 Jul;13(13):1513-1516
pubmed: 29998779
Sci Rep. 2017 Dec 14;7(1):17556
pubmed: 29242629
Cell Tissue Res. 2002 Dec;310(3):257-70
pubmed: 12457224
J Biomed Mater Res. 1989 Feb;23(2):253-66
pubmed: 2708412
J Neurooncol. 2007 Nov;85(2):133-48
pubmed: 17874037
Adv Mater. 2018 May 7;:e1705328
pubmed: 29736981
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396284
Histochem Cell Biol. 2018 Mar;149(3):219-233
pubmed: 29356965